CD274 and non-small cell lung carcinoma: In the first-line treatment of advanced NSCLC, the Impower110 trial showed that Atezolizumab monotherapy provided significant benefit over chemotherapy in patients with a high PD-L1 expression, offering another “chemotherapy waiver” treatment option (26).